Purchase this article with an account.
Luis Nakayama, Vinicius Campos Bergamo, Marina Lourenco Conti, Livia Costa, Nilva Simeren Bueno de Moraes, Orlando Ambrogini Junior; Retinal Avascular Foveal Zone as an systemic biomarker to evaluate Inflammatory Bowel disease control. Invest. Ophthalmol. Vis. Sci. 2019;60(9):4572.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Our study objective was to compare foveal avascular zone in patients with inflammatory bowel disease diagnosis, and try to correlate avascular foveal zone and disease activity.
We evaluated 72 patients with IBD trough complete ophthalmological exam and posterior segment exams. Color fundusretinography, OCT and OCT Angiography was performed with Topcon Triton (Topcon®, Tokyo, Japan). Macula and posterior pole were evaluated with binocular indirect ophthalmoscopy and Fundus Biomicroscopy. Avascular fovealzone was determined with manual delimitation of superficial retinal image at AngioOCT exam with image6.net software.
Participants mean age was 42.26 years (18-68), 28 male patients (38.88%) and 44 female patients (61.11%).37 with diagnosis of CrohnDisease (51,38%) and 35 patients with diagnosis of Ulcerative Colitis (48,61%).We didn’t found statistically difference between avascular foveal zone comparison between CD and RCU groups (p 0.91 for right eye and p 0.76 for left eye), but statistically difference comparing FAZ between remission and active group, in right and left eye (p 0.01 in right eye and p 0.02 in left eye).
We didn’t found difference in FAZ size between inflammatory bowel diseases (CD and RCU) parameters in both eyes.Patients with clinical and colonoscopy classification of active disease presented decreased avascular foveal zone comparing to patients with remission of disease.Avascular fovealzone evaluation presents as an ophthalmological parameters that is obtained non-invasively and is increased in ischemic diseases such as diabetic retinopathy.It can help to determine whether the patient is in remission or activity of IBD disease and even spare invasive exams in disease follow up.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.
This PDF is available to Subscribers Only